Anteris (ASX:AVR) share price soars 22% on successful human trial

The company’s shares are off to a strong start this week.
The post Anteris (ASX:AVR) share price soars 22% on successful human trial appeared first on The Motley Fool Australia. –

The Anteris Technologies Ltd (ASX: AVR) share price is shooting for the stars in early afternoon trade. This follows the structural heart company’s latest announcement that shows promising signs for its DurAVR THV system.

Anteris, formerly known as Admedus Ltd, is a medical company that focuses on designing and manufacturing heart valves. Its next-generation technology re-engineers xenograft tissue into pure collagen scaffold, helping surgeons replace values for patients during surgery.

At the time of writing, Anteris shares are roaring 18.24% higher to $10.50 after reaching a high of $10.90 earlier in the session. It’s worth noting that in the past month alone, the company’s shares have climbed 26% to a 6-month high.

Anteris successfully implants DurAVR valve

Investors are buying up Anteris shares after the company provided a positive announcement regarding its transcatheter aortic valve replacement (TAVR).

According to its release, Anteris advised it has successfully implanted the DurAVR value to five TAVR patients. The first-in-human study, carried out at the Tbilisi Heart and Vascular Clinic in Tbilisi, Georgia, showed great results.

No complications were detected among the five patients following their treatment. The trial assessed a number of performance and safety endpoints.

Anteris noted an additional five patients are planned for treatment in the first quarter of 2022 to conclude the study.

Anteris chief medical officer Dr Chris Meduri commented:

The meticulous preparation for this study has led to an outstanding set of results and patient outcomes. Not only did the valve performance exceed our very high expectations but the additional aspects of commissural alignment, flow characteristics and haemodynamics were proven to be clinically significant.

We are excited to now add more patients to our studies in 2022.

About the Anteris share price

On the back of today’s incredible gains, the Anteris share price is up by 190% since this time last year. Anteris shares reached a 52-week high of $13.75 in March, before moving in circles for most of 2021.

Based on today’s price, Anteris has a market capitalisation of roughly $95.13 million, with just 8.77 million shares on issue.

The post Anteris (ASX:AVR) share price soars 22% on successful human trial appeared first on The Motley Fool Australia.

Should you invest $1,000 in Anteris right now?

Before you consider Anteris, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and Anteris wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Poseidon Nickel (ASX:POS) share price booms 17% on ‘exceptional’ drilling results

Why is the Northern Star (ASX:NST) share price sinking 3% today?

Leading brokers name 3 ASX shares to buy today

What I learned about investing from my nephews

The Woolworths (ASX:WOW) share price is up 20% so far in 2021. Here’s why

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!